Recommended Articles
Fundraising

Bioliberty Raises $3.3M Series A Extension to Bring AI Rehab Technology Into Patients' Homes

By Angeled · November 7, 2026 · Fundraising
Bioliberty Raises $3.3M Series A Extension to Bring AI Rehab Technology Into Patients' Homes
Bioliberty Raises $3.3M Series A Extension to Bring AI Rehab Technology Into Patients' Homes

Bioliberty, a rehabilitation technology startup based in Edinburgh and Boston, has raised a €2.95 million ($3.3 million) Series A extension, bringing its total funding to €12.07 million ($13.5 million). The extension was reported on 6 November 2026.

The round adds four new institutional backers: TGH Ventures, the investment arm of Tampa General Hospital; Ballad Ventures; Belfast-based Whiterock; and 25m Health. It builds on €9.12 million ($10.2 million) previously raised through pre-Series A and Series A rounds. The overall Series A was led by a previously announced investment from the Scottish National Investment Bank, with participation from Archangels, Eos Advisory, Old College Capital, Hanna Capital SEZC and Conduit Connect.

What Bioliberty does

Bioliberty was founded in 2020 by Rowan Armstrong, Ross O'Hanlon, Conan Bradley and Shéa Quinn, graduates of the University of Edinburgh's School of Engineering. The company develops soft-robotic rehabilitation technology focused on upper-extremity recovery — helping patients regain hand and arm movement after a stroke or other neurological condition.

Its flagship product is Lifeglov, a soft robotic glove powered by air pressure that gently assists a patient in opening and strengthening their hand. Unlike a rigid exoskeleton, a soft robotic glove is pliable and comfortable, and it can be calibrated to each patient's individual ability level. The glove is part of the Lifehub Clinic system, which has three components:

  • Lifehub, a portable control centre that powers the system and delivers interactive, game-based therapy sessions.
  • Lifeglov, the soft robotic wearable glove itself.
  • Lifemind, a clinician-facing dashboard that centralises therapy data and uses AI to auto-generate clinical notes.

Lifehub and Lifeglov were FDA-registered in the United States in December 2024, and Bioliberty launched commercially in the US in 2025. Its technology is already in use at several leading American rehabilitation facilities, including Sheltering Arms Institute in Virginia. The company holds seven patents across its core technologies, is headquartered in Edinburgh with manufacturing in Fife, and opened a US headquarters in Boston in 2025.

Why stroke rehabilitation needs new tools

Stroke is one of the largest causes of long-term disability worldwide, and hand impairment is among its most common and most stubborn consequences. Up to 80% of stroke survivors experience upper-limb impairment early in recovery, and most do not regain full function after six months.

Recovery depends heavily on high-dose, repetitive task practice — the kind of therapy that promotes neuroplasticity, the brain's ability to rewire itself around damaged areas. But that therapy is labour-intensive: a therapist can only work with one patient at a time, and clinic capacity is limited. A device that lets patients practise more, with the right amount of assistance, and that records exactly what happened in each session, addresses a real bottleneck rather than a hypothetical one.

Gamification is part of the design. Patients wearing the glove practise through interactive, game-based exercises, which makes repetitive therapy more engaging and easier to sustain than rote exercises alone.

What is a Series A extension?

A Series A extension is additional capital raised on top of an existing Series A round, usually at similar terms, rather than a brand-new priced round. Companies use extensions for a few reasons: to bring in new strategic investors, to extend runway while they hit the milestones needed for a larger Series B, or to fund a specific expansion — in Bioliberty's case, moving from clinics into the home.

Extensions are generally a healthy sign when they add new institutional investors, as this one does. The presence of TGH Ventures is particularly notable: Tampa General Hospital is one of Bioliberty's clinical sites, so its venture arm is investing in a technology its own clinicians already use. That kind of customer-investor is a strong validation signal in health tech, where adoption by hospitals is the hardest part of the business.

What the money will fund

Bioliberty says the extension will support three priorities: extending its technology into the home environment, connecting rehabilitation data across different care settings, and building out additional AI capabilities to support clinical decision-making. It also plans to accelerate its US commercial rollout, expand clinical trials across partner hospital networks, scale its engineering and customer success teams, and advance hardware manufacturing.

The home move is the strategic heart of the round. Clinic-based rehabilitation ends when the patient is discharged; recovery does not. A home version would let therapy continue where the patient lives, with data flowing back to clinicians — a much larger market than clinic-only sales, but one that brings new challenges around home usability, remote support and reimbursement.

Why this matters for founders and investors

Bioliberty illustrates several patterns worth studying. First, university spinouts can work when the founding team stays close to the clinical problem: the company emerged from Edinburgh's School of Engineering and built its product with rehabilitation partners rather than in isolation.

Second, health-tech fundraising rewards evidence over hype. FDA registration, deployment in real hospitals and patents are the milestones that unlocked this extension; the AI features are presented as a way to reduce clinician paperwork, not as a standalone miracle.

Angeled.com connects founders with investors.

Read Next